| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5709219 | The Journal of Arthroplasty | 2017 | 22 Pages |
Abstract
This prospective, observational, phase IV study demonstrates that rivaroxaban appears to protect patients against symptomatic PE and is not associated with major bleeding events when used in a real-world setting as described.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
David MD, PhD, Helen PhD, Andrea MD, Vikas B. MD, Jeffrey D. BASc, MD, John J. MD, MSc, MA,